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doi:10.1Objective: The present study evaluated the mortality and conduit failure in bovine jugular vein (BJV) conduits.
Methods: Between October 1999 and February 2009, 193 patients (mean age, 6.7 5.8 years; range, 5 days to
18 years; mean weight, 23.9  21.0 kg; range, 2.4-105.4 kg) had been discharged after BJV implantation. The
reason for BJV implantation was right ventricular outflow tract reconstruction in 117 conduit replacement in 44,
and the Ross procedure in 32. The diameter of the BJV was 12 mm in 18 patients (9.3%), 14 mm in 16 (8.3%),
16 mm in 42 (21.7%), 18 mm in 37 (19.2%), 20 mm in 15 (7.8%), and 22 mm in 65 (33.7%).
Results:At amean SD follow-up of 4.6 2.3 y/patient (range, 8 months to 10 years), 5 late deaths (2.6%) had
occurred, all unrelated to conduit failure. Conduit-related problems required an interventional procedure as the
first treatment in 10 patients (5.2%) within a mean interval of 2.5  1.4 years (range, 8 months to 5.3 years) or
surgical revision in 5 patients (2.6%) after 2.1 1.9 years (range, 19 days to 4.1 years). Late deaths occurred in
5.9% (2/34) of patients with a BJV size of 12 to 14 mm versus 1.9% (3/159) in patients with a size of 16 to 22
mm (P ¼ NS). An interventional procedure or surgical revision was required in 29.4% (10/34) of patients with
a BJV size of 12 to 14 mm versus 3.1% (5/159) in patients with a size of 16 to 22 mm (P<.0005).
Conclusions: After 10 years of experience with the BJV, this conduit has remained a reliable alternative to
pulmonary homografts with respect to survival and freedom from conduit failure. However, the incidence
was greater and the presentation of conduit failure was earlier in patients with a smaller size BJV conduit
(12-14 mm). (J Thorac Cardiovasc Surg 2011;141:983-987)C
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The search for the ideal conduit to repair congenital heart
defects has prompted investigation of various alternatives,
including homografts; xenograft valves in Dacron, polytetra-
fluoroethylene, or pericardial conduits; stented and non-
stented xenografts; and, more recently, tissue-engineered
conduits. Pulmonaryhomografts, the conduit of choice inpre-
vious decades, have been limited by the smaller sizes, scarce
availability, and potential for obstruction and calcification.1,2
The bovine jugular vein (BJV) (Contegra, Medtronic Inc,
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The Journal of Thoracic and Caan alternative to the use of homografts in 1999 and has
provided encouraging results in several reported clinical
series.1,3-12
The recognized advantages of the BJV include the struc-
tural continuity between the wall of the jugular vein of the
conduit and valve leaflets, which provides optimal hemody-
namics because of the ideal effective orifice area; the unlim-
ited ‘‘off-the-shelf’’ availability in sizes from 12 to 22 mm
in diameter, representing a good alternative to the homo-
graft shortage, particularly for the smaller sizes; the avail-
ability of a long length at both inflow and outflow that
obviates the need for either proximal or distal augmentation
and facilitating conduit tailoring and positioning that helps
to avoid potential distortion and sternal compression; and
exceptional reports of antigenic reaction because of glutar-
aldehyde fixation.
The main indication for this conduit remains right ven-
tricular outflow tract reconstruction for complex congenital
heart defects, either as an initial procedure requiring valved
conduit implantation or at conduit replacement. After its
successful introduction as the pulmonary valve replacement
for the Ross operation,13 its use has also been expanded to
this indication.8,11,12,14
In contrast to thegoodclinical results obtained fromseveral
institutions,3-11 a disturbing sequence of publications has
reported stenosis at the level of the distal anastomosis of the
conduit, with proximal conduit dilatation, aneurysm, or
pseudoaneurysm, in 6% to 50% of patients.4-6,8,15-23rdiovascular Surgery c Volume 141, Number 4 983
TABLE 1. Distribution of diagnosis
Indication Diagnosis Patients (n)
RVOT reconstruction 117
Tetralogy of Fallot 28
Absent PV 5
Complete AVSD 5
PA, VSD 28
PV regurgitation after
TF repair
21
TGA, VSD, PS/PA 16
Truncus arteriosus 13
Abbreviation and Acronym
BJV ¼ bovine jugular vein
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DIn the present retrospective, single-center study, we eval-
uated the outcomes of BJV conduits during a follow-up of
up to 10 years, with particular attention to late mortality
and conduit failure requiring a surgical or catheter interven-
tional procedure.Aortic arch interruption 1
DORV, VSD, PS 9
PA, IVS 2
Conduit replacement 44
PA, VSD 14
Tetralogy of Fallot 12
Absent PV 1
Truncus arteriosus 12
TGA, VSD, PS/PA 5
DORV, VSD, PS 1
Ross procedure 32
Aortic valve stenosis 13
Aortic valve regurgitation 12
Aortic valve stenosis/
regurgitation
7
RVOT, Right ventricular outflow tract; PV, pulmonary valve; AVSD, atrioventricular
septal defect; PA, pulmonary atresia; VSD, ventricular septal defect; TF, tetralogy
of Fallot; TGA, transposition of great arteries; PS, pulmonary stenosis; DORV,
double-outlet right ventricle; IVS, intact ventricular septum.MATERIALS AND METHODS
The medical records of all patients in whom a BJV had been implanted
were reviewed. Our institutional review board approved the study.
The data collection and analysis included the demographic data, diagno-
sis, previous interventional and surgical procedures, the indication for BJV
implantation, the size of the implanted conduit, the duration of aortic cross-
clamping and cardiopulmonary bypass, the duration of the intensive care
unit and hospital stay, the outcomes, including early (in-hospital or within
30 days after surgery) and late deaths, and all episodes of catheter interven-
tion and/or surgery because of conduit failure. The point of conduit failure
was defined as the interval between BJV implantation and the first required
treatment. The choice between catheter intervention and surgery was de-
cided by the interventional cardiologists and surgeons, taking into consid-
eration the type of obstruction, such as a catheter procedure for patients
with limited stenosis and conduit replacement for patients who were
outgrowing the conduit.
Postoperatively, all patients had received intravenous heparin (10 U/kg/
h). This was transitioned before hospital discharge to antiplatelet treatment
(aspirin at 3 mg/kg/d) for 1 year.
All patients were followed with clinical examination and serial transtho-
racic echocardiography every 6 to 12 months until October 2009.
Statistical Analysis
Continuous variables were calculated as the mean standard deviation.
Comparative analyses were performed using paired Student’s t and c2 tests.
Patient survival and freedom from conduit failure were determined using
the Kaplan-Meier method and the Wilcoxon test.RESULTS
Demographic Data
Between October 1999 and February 2009, 198 patients
had undergone BJV implantation.
The surgical indications included right ventricular out-
flow tract reconstruction in 120 patients, conduit replace-
ment in 46, and the Ross procedure in 32.
For the purposes of the present study, we excluded from
the data analysis, all patients with an early death (n¼ 5), all
of which were unrelated to the conduit.
The study population therefore included 193 patients,
109 males (56.5%) and 84 females (43.5%), with a mean
age of 6.7  5.8 years (range, 5 days to 18 years) and
mean weight of 23.9  21.0 kg (range, 2.4 to 105.4 kg) at
BJV implantation.
The specific diagnosis for each group is listed in Table 1.
Of the 193 patients, 138 (71.5%) had previously under-
gone surgery, for a total of 158 procedures, including 44984 The Journal of Thoracic and Cardiovascular Surgpatients who had undergone previous conduit implantation
(Table 2).
The diameter of the implanted BJV, decided by the sur-
geon on the basis of the expected size of the pulmonary
artery for the patient’s age and body weight, was 12 mm
for 18 patients (9.3%), 14 mm in 16 (8.3%), 16 mm in
42 (21.7%), 18 mm in 37 (19.2%), 20 mm in 15 (7.8%),
and 22 mm in 65 patients (33.7%).Late Mortality
At a mean follow-up period of 4.6 2.3 y/patient (range,
8 months to 10 years), 5 late deaths (2.6%) had occurred,
all unrelated to conduit failure. Of the 5 patients who
died, 4 had had right ventricular outflow tract reconstruc-
tion (4/117 ¼ 3.4%). The diagnosis was truncus arteriosus
in 1 patient; pulmonary valve regurgitation after repair of
tetralogy of Fallot in 1 patient; double-outlet right ventricle
with ventricular septal defect and pulmonary stenosis in 1
patient; and, in the last patient, transposition of the great
arteries with ventricular septal defect and pulmonary
stenosis. The fifth patient died after conduit replacement
(1/44 ¼ 2.3%). No late deaths occurred in the group of pa-
tients undergoing a Ross procedure. The overall survival
rate at 10 years was 96% (Figure 1). Late deaths in relation
to the surgical indication are summarized in Table 3.ery c April 2011
TABLE 2. Previous procedures
Procedure Specification Patients (n)
Systemic-pulmonary shunt 71
Modified Blalock-Taussig 59
Right 42
Bilateral 9
Left 8
Central shunt 10
Waterston 2
Conduit replacement 44
Homograft 40
Shellhigh 2
Contegra (infection) 1
Biocore 1
Aortic valve procedure 22
Balloon dilation 17
23 1
33 2
43 1
Open valvotomy 4
Valve repairþVSD closure 1
RVOT enlargement 5
With VSD closure 3
Pulmonary artery banding 4
Aortic coarctectomy 4
Aortic arch repairþD-K-S 3
Pacemaker implantation 2
Norwood/Sano 1
Arterial switch 1
Subaortic resection 1
VSD, Ventricular septal defect; RVOT, right ventricular outflow tract; D-K-S, Damus-
Kaye-Stansel procedure.
TABLE 3. Late mortality and conduit failure in relation to surgical
indication
Indication Patients (n)
Late
death (n)
Conduit
failure (n)
RVOT reconstruction 117 4 (3.4%) 10 (8.5%)
Conduit replacement 44 1 (2.3%) 4 (9.1%)
Ross procedure 32 0 (0%) 1 (3.1%)
RVOT, Right ventricular outflow tract.
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DConduit Failure
Conduit-related problems necessitated an interventional
procedure as the first treatment in 10 patients (5.2%) within
a mean interval of 2.5  1.4 years (range, 8 months to 5.3
years) and surgical revision in 5 patients (2.6%) after
2.1  1.9 years (range, 19 days to 4.1 years).
Of the 10 patients requiring a catheter-based intervention
as the first treatment of conduit failure, 3 (30%) required
a second catheter intervention after 4, 12, and 30 monthsFIGURE 1. Overall survival. Total number of patients enrolled during
follow-up, excluding late deaths, indicated every 2 years.
The Journal of Thoracic and Ca(followed by surgery in 1) and 2 (20%) required surgery
as the subsequent treatment after 24 and 45 months. The re-
maining 5 patients undergoing a catheter-based intervention
had not required any additional treatment after a mean inter-
val of 35  17 months (range, 17 to 58 months).
Conduit failure had resulted from obstruction in 14 (93%)
and valve regurgitation in 1 (7%) of 15 patients and was
never because of BJV calcification, even in the smaller size
conduits. The overall freedom from conduit failure rate at
10 years was 90% (Figure 2). The conduit failure data are
summarized in Table 3 stratified by the surgical indication.
Conduit Size
Late deaths occurred in 5.9% (2/34) of the patients with
a BJV size of 12 to 14 mm versus 1.9% (3/159) of the pa-
tients with a size of 16 to 22 mm (P ¼ NS).
Catheter intervention or surgical revision was required in
10 (29.4%) of 34 patients with a BJV conduit of 12 to
14 mm versus 5 (3.1%) of 159 patients with 16 to 22 mm
(P<.0005).
The late deaths and conduit failures in relation to BJV
size are summarized in Table 4, and the statistical analysis
results of the late mortality and conduit failure in relation to
the BJV conduit size are summarized in Table 5.
Kaplan-Meier curves showing the survival and successful
use of a BJV conduit (ie, freedom from intervention) are re-
ported in Figures 3 and 4, respectively.
An infant who had developed conduit endocarditis
9 months after BJV implantation for pulmonary atresia with
ventricular septal defect required conduit replacement.FIGURE 2. Overall freedom from intervention. Total number of patients
enrolled in during follow-up, excluding late deaths and patients who under-
went intervention, indicated every 2 years.
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TABLE 4. Late mortality and conduit failure in relation to BJV
conduit size
Size (mm) Patients (n) Late death (n) Conduit failure (n)
12 18 1 (5.6%) 5 (27.8%)
14 16 1 (6.3%) 5 (31.3%)
16 42 0 (0%) 2 (4.8%)
18 37 2 (5.4%) 1 (2.7%)
20 15 0 (0%) 1 (6.7%)
22 65 1 (1.5%) 1 (1.5%)
BJV, Bovine jugular vein.
FIGURE 3. Survival comparing different sizes of bovine jugular vein
(BJV): 12 to 14 mm versus 16 to 22 mm. Total number of patients enrolled
during follow-up, excluding late deaths, indicated every 2 years.
Congenital Heart Disease Prior et al
C
H
DAlthough the reoperation was related to the conduit, this pa-
tientwas not included in the primary conduit failure group be-
cause the reason for reoperation was infection rather than
hemodynamic deterioration.
DISCUSSION
The present 10-year study evaluated the long-term out-
comes after BJV implantation, with particular attention to
survival and conduit durability, defined as freedom from
an interventional procedure or surgery required for conduit
failure.
Our clinical experience with the BJV is the largest re-
ported single-center series of patients with up to 10 years
of follow-up. Our results have confirmed the good results
reported by other smaller series3-11 with respect to
survival and freedom from conduit failure, with an overall
survival rate greater than 96% at 10 years (Figure 1) and
an overall freedom from conduit failure rate greater than
90% at 10 years (Figure 2).
No difference was seen in survival or the freedom from
conduit failure between the first implantation for right ven-
tricular outflow tract reconstruction and conduit replace-
ment. The BJV provided very good results in the Ross
procedure, with no latemortality and only 1 patient requiring
conduit replacement 4 years after a neonatal Ross procedure.
The significantly greater incidence (29.4% vs 3.1%,
P<.0005) of conduit failure observed with the smaller (12
and 14mm)comparedwith the larger (16 to22mm)BJVcon-
duitswas directly related to the patients’ age and bodyweightTABLE 5. Statistical analysis of late mortality and conduit failure in
relation to BJV conduit size
Variable
Size (mm)
P value12–14 16–22
Patients 34 159
Age (y) < .0001
Mean 1.2 7.8
Range 3 d to 8.9 y 22 d to 17.9 y
Weight (kg) < .0001
Mean 6.9 27.5
Range 2.4–38.9 2.7–105.4
Late death 2 (5.9%) 3 (1.9%) NS
Conduit failure 10 (29.4%) 5 (3.1%) < .0005
BJV, Bovine jugular vein; NS, not statistically significant.
986 The Journal of Thoracic and Cardiovascular Surgat implantation (Table 4). This conduit failure resulted from
the patient outgrowing the conduit. This has been a recurrent
problem observed in small patients, independent of the type
of biologic valved conduit used, because a difficult balance
must be reached among the need to limit the size of the ven-
triculotomy, the space available in the mediastinum, and the
instinct to implant the largest possible conduit.1,2,6,16
The problem of conduit dilatation related to obstruction at
the distal anastomosis has been reported as a specific compli-
cation of BJV conduits.15-23 The following mechanisms have
been recognized as potential causes of distal stenosis:
the presence of hypoplasia and/or distal stenosis of the
pulmonary artery branches; a discrepancy in the size
between the conduit and pulmonary artery; the surgical
technique used; a local immunologic/inflammatory reaction;FIGURE 4. Freedom from intervention stratified by bovine jugular vein
(BJV) size: 12 to 14 mm versus 16 to 22 mm. Total number of patients en-
rolled during follow-up, excluding late deaths and patients who underwent
intervention, indicated every 2 years.
ery c April 2011
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more of these factors.24
The effect of the surgical technique has been previously
studied using computational fluid dynamics to compare 2
types of distal anastomosis: the conventional end-to-end
‘‘circular’’ anastomosis versus the oblique ‘‘elliptical’’
anastomosis, with the incision extended on to the anterior
aspect of the left pulmonary artery and the distal end of
the conduit obliquely tailored. That study confirmed a larger
cross-sectional area in the ‘‘elliptical’’ compared with the
‘‘circular’’ type of anastomosis, along with a more homoge-
neous velocity, pressure, and shear stress distribution.24
These results suggested that the ‘‘elliptical’’ anastomosis
might reduce the incidence and degree of distal stenosis,
particularly for smaller conduits. Therefore, we adopted
this technique for the distal anastomosis, in addition to care-
ful rinsing (5 minutes, three times, in different saline solu-
tions) before implantation to clear the glutaraldehyde and
reduce the inflammatory reaction and avoidance of oversize
conduits to reduce the discrepancy between the conduit and
distal pulmonary artery size. Using this protocol, distal con-
duit stenosis has become a rare complication in our experi-
ence, even with the smaller conduits.
Early calcification of biologic valved conduits has been
frequently reported with homografts, particularly in infants
or small children in the first fewyears of age.1,2 In the present
study, early conduit calcification causing hemodynamic
consequences was never observed, confirming our own
previous observations and those of other investigators.4-6,8
Despite the encouraging results of our study, we recog-
nize the need to continue to investigate alternative surgical
options, such as the valveless conduit and the monocusp
transannular patch, to minimize the use of valved conduits
in small infants. These surgical approaches would delay re-
operation, making implantation of a larger size BJV conduit
more feasible.
CONCLUSIONS
After 10 years of experience with BJV, this conduit has
remained a reliable alternative to pulmonary homografts,
which are still considered the first choice when a biologic
valved conduit is required. The incidence of conduit failure
was greater and the presentation was earlier in patients with
a smaller size BJV (12-14 mm). Alternative surgical ap-
proaches should be investigated to avoid the use of smaller
size conduits in small infants.
We are grateful to Dr. Tom Karl, Brisbane, Australia, for his re-
view of the manuscript and helpful comments.
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